Drug Type Small molecule drug  | 
Synonyms HQK-1004, VX-105  | 
Target  | 
Action stimulants  | 
Mechanism thymidine kinase stimulants(Thymidine kinase stimulants)  | 
Active Indication  | 
Inactive Indication  | 
Originator Organization  | 
Active Organization  | 
Inactive Organization  | 
License Organization-  | 
Drug Highest PhasePreclinical  | 
First Approval Date-  | 
RegulationOrphan Drug (United States)  | 
Molecular FormulaC10H22N4O4  | 
InChIKeyHTWPXGKLFMPZHG-WCCKRBBISA-N  | 
CAS Registry80407-72-3  | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Epstein-Barr virus positive Lymphoma | Phase 2 | United States   | 01 May 2010 | |
| Epstein-Barr Virus-Related Lymphoma | Phase 2 | United States   | 01 Sep 2008 | |
| Anemia, Sickle Cell | Phase 2 | United States   | 01 Sep 1997 | |
| Beta-Thalassemia | Phase 2 | United States   | 01 Sep 1997 | |
| Leg Ulcer | Phase 2 | United States   | 01 Sep 1997 | |
| Short Bowel Syndrome | Preclinical | United States   | 09 Mar 2023 | 
Phase 2  | 23  | Standard local care dressing (Standard Local Care Dressing)  | pnosfbtjok = oxazxcsebj sncpabqxtj  (gtwokrcpzc, dlnnpqgzxf - lilfebalgu) View more  | -  | 31 Mar 2015  | ||
Standard local care dressing+Arginine Butyrate (Arginine Butyrate)  | pnosfbtjok = oxufcycxng sncpabqxtj  (gtwokrcpzc, uxfheogccn - mohqkabrsj) View more  | ||||||
Phase 2  | - | (Standard local care)  | uupmnopvzd(nnjzxjaulh) = hzznrqwmky mdegyknrjo (qziprsbimx )  | -  | 01 Dec 2010  | ||
Standard care with Arginine Butyrate  | uupmnopvzd(nnjzxjaulh) = rnantcchpe mdegyknrjo (qziprsbimx )  | ||||||
Phase 1/2  | 15  | zvajrlfeny(qxxxusnkge) = lgymmkrllm zfxkjeekfu (cxdjriykab )  | -  | 15 Mar 2007  | |||
Phase 1/2  | - | epnosikygd(xkqluuhjso) = wnvdrucvou twfiiftmam (pnefpziial )  | -  | 20 Jun 2006  | 





